Reuters Market Eye - Shares in Cipla Ltd on Tuesday rose as much as 8.7 percent to a record high of 575 rupees after the drugmaker launched an anti-asthma inhaler in Germany and Sweden.
The inhaler is a generic version of GlaxoSmithKline Plc's Advair.
Emkay Global upgraded the stock to "buy" from "accumulate" with a target of 671 rupees.
Overall addressable opportunity of generic Advair is $800 million in Europe, Emkay said.
Cipla shares were trading up 5.2 percent to 556.55 rupees as of 3:16 p.m.
(Reporting by Abhishek Vishnoi)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app